Merck & Co ($MRK (+2,71 %) ) reports Q1 2025 earnings:
Q1 2025:
Sales: 15.53B vs. 15.33B expected (+1.3%) 🟡
Net Income: 5.08B vs. 4.98B expected (+2.01%) 🟡
Outlook for FY2025:
Sales: 64.85B vs. 65.01B expected (-0.25%) 🟡
Net Income: 20.4B vs. 20.36B expected (+0.2%) 🟡
“Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Robert M. Davis, chairman and chief executive officer, Merck. “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”